Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Weibin Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6659-9680; OpenAlex author ID A5100667347. Sources: OpenAlex.

Their work

Papers
38 (first author 2, last author 23)
Trials
0
Grants
0
Labs led
1
Collaborators
67
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: 5 papers · 2023: 4 papers · 2024: 6 papers · 2025: 5 papers · 2026: 6 papers

Papers 38

  1. Identifying a better-prognosis pancreatic cancer from its benign inflammatory mimic: a machine learning approach with contrast-enhanced ultrasound for early in… Co-author DOI 10.1007/s00261-026-05423-2↗
  2. Acinar-ductal metaplasia in pancreatitis and pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s13402-026-01251-0↗
  3. A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccell.2026.03.021↗
  4. Effect of TGFβ-ITGB6 feedback loop on liver metastasis in SMAD4 wild-type pancreatic cancer. Last author DOI 10.1097/cm9.0000000000003722↗
  5. Photon-counting CT for pancreatic cancer: advancing precision imaging and virtual surgical navigation. Co-author DOI 10.1097/jp9.0000000000000233↗
  6. Multidimensional 5-hydroxymethylcytosine features in cell-free DNA enable the detection, staging and subtyping of pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s40364-026-00988-y↗
  7. RNA binding protein Pumilio2 promotes chemoresistance of pancreatic cancer via focal adhesion pathway and interacting with transcription factor EGR1. Co-author DOI 10.1007/s00018-025-05599-8↗
  8. Development and validation of a nomogram model based on ultrasound and contrast-enhanced ultrasound features for differentiating mass-forming pancreatitis and … Co-author DOI 10.1007/s00261-025-05035-2↗
  9. Phthalocyanine and photodynamic therapy relieve albumin paclitaxel and gemcitabine chemoresistance in pancreatic cancer. Last author DOI 10.1016/j.yexcr.2025.114455↗
  10. Global, regional, and national burden of pancreatic cancer from 1990 to 2021, its attributable risk factors, and projections to 2050: a systematic analysis of … Last author DOI 10.1186/s12885-025-13597-z↗
  11. Extracellular vesicles-miR-205-5p inhibits lymphatic metastasis in pancreatic cancer through diffusely downregulating VEGFA. Last author DOI 10.7150/jca.110659↗
  12. Extracellular vesicles miR-31-5p promotes pancreatic cancer chemoresistance via regulating LATS2-Hippo pathway and promoting SPARC secretion from pancreatic st… Co-author DOI 10.1002/jev2.12488↗
  13. IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. Last author DOI 10.1007/s13402-024-00925-x↗
  14. Circulating tumor cells in pancreatic cancer: more than liquid biopsy. Last author DOI 10.1177/17588359241284935↗
  15. The systematic role of pancreatic cancer exosomes: distant communication, liquid biopsy and future therapy. Last author DOI 10.1186/s12935-024-03456-5↗
  16. Development and validation of a nomogram model based on pretreatment ultrasound and contrast-enhanced ultrasound to predict the efficacy of neoadjuvant chemoth… Co-author DOI 10.1186/s40644-024-00662-2↗
  17. Construction of a prognostic model with exosome biogenesis- and release-related genes and identification of RAB27B in immune infiltration of pancreatic cancer. Last author DOI 10.21037/tcr-24-54↗
  18. Retraction Note: IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. Last author DOI 10.1007/s13402-023-00897-4↗
  19. Prognostic value and immune infiltration of ARMC10 in pancreatic adenocarcinoma via integrated bioinformatics analyses. Last author DOI 10.1016/j.heliyon.2023.e20464↗
  20. EGR1 induces EMT in pancreatic cancer via a P300/SNAI2 pathway. Last author DOI 10.1186/s12967-023-04043-4↗
  21. DHX38 restricts chemoresistance by regulating the alternative pre-mRNA splicing of RELL2 in pancreatic ductal adenocarcinoma. Last author DOI 10.1371/journal.pgen.1010847↗
  22. Phospholipase A/acyltransferase 4 is a prognostic biomarker and correlated with immune infiltrates in pancreatic cancer. Last author DOI 10.1016/j.heliyon.2022.e10416↗
  23. CHRNB2 represses pancreatic cancer migration and invasion via inhibiting β-catenin pathway. Last author DOI 10.1186/s12935-022-02768-8↗
  24. Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugs. Last author DOI 10.1186/s12935-022-02785-7↗
  25. Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugs Last author DOI 10.21203/rs.3.rs-1759071/v2↗
  26. Long Noncoding RNA and Circular RNA: Two Rising Stars in Regulating Epithelial-Mesenchymal Transition of Pancreatic Cancer. Last author DOI 10.3389/fonc.2022.910678↗
  27. Mobius strip in pancreatic cancer: biogenesis, function and clinical significance of circular RNAs. Last author DOI 10.1007/s00018-021-03908-5↗
  28. IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. Last author DOI 10.1007/s13402-021-00651-8↗
  29. The role of autophagy in pancreatic cancer progression. Last author DOI 10.1016/j.bbcan.2021.188592↗
  30. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Co-author DOI 10.1186/s12943-020-01169-7↗
  31. Pancreatic Cancer With Ovarian Metastasis: Clinical Features, Diagnosis and Management Last author DOI 10.21203/rs.3.rs-32859/v1↗
  32. A novel prognostic marker and immunogenic membrane antigen: prohibitin (PHB) in pancreatic cancer. Co-author DOI 10.1038/s41424-018-0044-1↗
  33. MicroRNA-21 induces 5-fluorouracil resistance in human pancreatic cancer cells by regulating PTEN and PDCD4. First author DOI 10.1002/cam4.626↗
  34. MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells. Co-author DOI 10.1038/srep27641↗
  35. A Single Talent Immunogenic Membrane Antigen and Novel Prognostic Predictor: voltage-dependent anion channel 1 (VDAC1) in Pancreatic Cancer. Co-author DOI 10.1038/srep33648↗
  36. Increased expression of Nodal correlates with reduced patient survival in pancreatic cancer. First author DOI 10.1016/j.pan.2015.02.001↗
  37. Recent studies of 5-fluorouracil resistance in pancreatic cancer. Co-author DOI 10.3748/wjg.v20.i42.15682↗
  38. [Validation of candidate immunogenic membrane antigens of human pancreatic cancer screened by proteomics]. Co-author PMID 22800753↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zeru Li · 21 shared papers, 2021–2026 · strength 4.52
  2. Bangbo Zhao · 22 shared papers, 2018–2026 · strength 4.48
  3. Yuanyang Wang · 14 shared papers, 2021–2024 · strength 2.48
  4. Cheng‐Feng Qin · 11 shared papers, 2021–2024 · strength 2.04
  5. Yutong Zhao · 8 shared papers, 2022–2025 · strength 1.80
  6. Tianyu Li · 8 shared papers, 2022–2025 · strength 1.76
  7. Xiaoying Yang · 10 shared papers, 2021–2024 · strength 1.68
  8. Cheng Qin · 6 shared papers, 2020–2026 · strength 1.41
  9. Cheng Yong Qin · 6 shared papers, 2022–2025 · strength 1.35
  10. Tianyu Li · 4 shared papers, 2024–2025 · strength 1.02
  11. Yutong Zhao · 3 shared papers, 2026 · strength 0.96
  12. Tianhao Li · 6 shared papers, 2020–2023 · strength 0.95
  13. Menghua Dai · 4 shared papers, 2024–2026 · strength 0.87
  14. Tianhao Li · 5 shared papers, 2021–2024 · strength 0.84
  15. Xingtong Zhou · 5 shared papers, 2020–2024 · strength 0.83
  16. Yupei Zhao · 6 shared papers, 2016–2026 · strength 0.75
  17. Yuanyang Wang · 2 shared papers, 2025 · strength 0.54
  18. Junchao Guo · 2 shared papers, 2025–2026 · strength 0.48
  19. Ke Lv · 2 shared papers, 2024–2026 · strength 0.44
  20. Haoyu Shi · 1 shared paper, 2026 · strength 0.32
  21. Xiangyu Zhang · 1 shared paper, 2026 · strength 0.29
  22. Yiping Xie · 1 shared paper, 2026 · strength 0.29
  23. Jing-Yi Liu · 1 shared paper, 2026 · strength 0.29
  24. Feng Feng · 1 shared paper, 2026 · strength 0.29
  25. Haoyu Shi · 1 shared paper, 2026 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.